Willson Douglas F, Chess Patricia R, Notter Robert H
Pediatric ICU and Division of Pediatric Critical Care, University of Virginia Children's Medical Center, UVA Health Sciences System, Box 800386, Charlottesville, VA 22908-0386, USA.
Pediatr Clin North Am. 2008 Jun;55(3):545-75, ix. doi: 10.1016/j.pcl.2008.02.016.
This article reviews exogenous surfactant therapy and its use in mitigating acute lung injury (ALI) and the acute respiratory distress syndrome (ARDS) in infants, children, and adults. Biophysical and animal research documenting surfactant dysfunction in ALI/ARDS is described, and the scientific rationale for treatment with exogenous surfactant is discussed. Major emphasis is placed on reviewing clinical studies of surfactant therapy in pediatric and adult patients who have ALI/ARDS. Particular advantages from surfactant therapy in direct pulmonary forms of these syndromes are described. Also discussed are additional factors affecting the efficacy of exogenous surfactants in ALI/ARDS.
本文综述了外源性表面活性剂疗法及其在减轻婴儿、儿童和成人急性肺损伤（ALI）和急性呼吸窘迫综合征（ARDS）中的应用。文中描述了记录ALI/ARDS中表面活性剂功能障碍的生物物理和动物研究，并讨论了使用外源性表面活性剂治疗的科学依据。重点在于综述患有ALI/ARDS的儿科和成人患者的表面活性剂疗法临床研究。阐述了表面活性剂疗法在这些综合征直接肺损伤形式中的特殊优势。还讨论了影响外源性表面活性剂在ALI/ARDS中疗效的其他因素。
